[6-K] ICL Group Ltd. Current Report (Foreign Issuer)
Rigel Pharmaceuticals filed a Form S-8 to register 825,000 additional common shares for issuance under its employee equity plans: 125,000 shares for the Inducement Plan and 700,000 shares for the 2018 Equity Incentive Plan. The filing relies on General Instruction E, incorporating prior S-8s by reference and therefore only covers the incremental shares. No new financial statements or business updates are provided; the document simply expands the share pool available for recruiting, retention and general employee compensation purposes. Standard exhibits include the legal opinion, audit consent, and updated plan documents. The registration may result in modest dilution when shares are issued, but enables the company to continue using equity incentives without immediate cash impact.
Rigel Pharmaceuticals ha presentato un modulo Form S-8 per registrare 825.000 azioni ordinarie aggiuntive da emettere nell'ambito dei suoi piani azionari per i dipendenti: 125.000 azioni per il Piano di Incentivazione e 700.000 azioni per il Piano di Incentivi Azionari 2018. La presentazione si basa sull'Istruzione Generale E, incorporando per riferimento precedenti moduli S-8 e coprendo quindi solo le azioni incrementali. Non vengono forniti nuovi bilanci o aggiornamenti aziendali; il documento amplia semplicemente il numero di azioni disponibili per reclutamento, fidelizzazione e compensi generali ai dipendenti. Gli allegati standard includono il parere legale, il consenso alla revisione e i documenti aggiornati dei piani. La registrazione potrebbe causare una diluizione modesta al momento dell'emissione delle azioni, ma consente all'azienda di continuare a utilizzare incentivi azionari senza un impatto immediato in contanti.
Rigel Pharmaceuticals presentó un Formulario S-8 para registrar 825,000 acciones comunes adicionales para emisión bajo sus planes de acciones para empleados: 125,000 acciones para el Plan de Incentivos y 700,000 acciones para el Plan de Incentivos de Capital 2018. La presentación se basa en la Instrucción General E, incorporando formularios S-8 previos por referencia y por lo tanto solo cubre las acciones adicionales. No se proporcionan nuevos estados financieros ni actualizaciones comerciales; el documento simplemente amplía el grupo de acciones disponibles para reclutamiento, retención y compensación general a empleados. Los anexos estándar incluyen la opinión legal, el consentimiento de auditoría y los documentos actualizados del plan. El registro puede resultar en una dilución modesta cuando se emitan las acciones, pero permite a la empresa continuar usando incentivos de capital sin un impacto inmediato en efectivo.
Rigel Pharmaceuticals� 직원 주식 계획� 따라 발행� 추가 보통� 825,000�� 등록하기 위해 Form S-8� 제출했습니다: 유인 계획� 125,000�, 2018� 주식 인센티브 계획� 700,000주입니다. � 제출은 일반 지� E� 기반으로 하며 이전 S-8� 참조� 포함하여 증분 주식만을 다룹니다. 새로� 재무제표� 사업 업데이트� 제공되지 않으�, 단지 직원 채용, 유지 � 일반 보상 목적으로 사용 가능한 주식 풀� 확장하는 내용입니�. 표준 부� 서류에는 법률 의견�, 감사 동의� � 업데이트� 계획 문서가 포함됩니�. 등록은 주식 발행 � 다소 희석 효과� 초래� � 있지�, 회사가 즉각적인 현금 영향 없이 주식 인센티브� 계속 사용� � 있게 합니�.
Rigel Pharmaceuticals a déposé un formulaire S-8 pour enregistrer 825 000 actions ordinaires supplémentaires à émettre dans le cadre de ses plans d'actionnariat salarié : 125 000 actions pour le Plan d'Incitation et 700 000 actions pour le Plan d'Incitation en Actions 2018. Le dépôt s'appuie sur l'Instruction Générale E, incorporant par référence les précédents formulaires S-8 et couvre donc uniquement les actions supplémentaires. Aucun nouvel état financier ou mise à jour commerciale n'est fourni ; le document élargit simplement le nombre d'actions disponibles pour le recrutement, la rétention et la rémunération générale des employés. Les annexes standard incluent l'avis juridique, le consentement d'audit et les documents de plan mis à jour. L'enregistrement peut entraîner une dilution modérée lors de l'émission des actions, mais permet à l'entreprise de continuer à utiliser des incitations en actions sans impact immédiat sur la trésorerie.
Rigel Pharmaceuticals reichte ein Formular S-8 ein, um 825.000 zusätzliche Stammaktien zur Ausgabe im Rahmen seiner Mitarbeiterbeteiligungspläne zu registrieren: 125.000 Aktien für den Anreizplan und 700.000 Aktien für den Aktienanreizplan 2018. Die Einreichung stützt sich auf die Allgemeine Anweisung E, die frühere S-8-Formulare durch Verweis einbezieht und daher nur die zusätzlichen Aktien abdeckt. Es werden keine neuen Finanzberichte oder Geschäftsaktualisierungen bereitgestellt; das Dokument erweitert lediglich den Aktienpool, der für Rekrutierung, Bindung und allgemeine Mitarbeitervergütung zur Verfügung steht. Standardmäßig enthaltene Anlagen sind die Rechtsmeinung, die Prüfungszustimmung und aktualisierte Planunterlagen. Die Registrierung kann bei Ausgabe der Aktien zu einer moderaten Verwässerung führen, ermöglicht dem Unternehmen jedoch, weiterhin Aktienanreize ohne unmittelbare Liquiditätsauswirkungen zu nutzen.
- Supports talent acquisition and retention by ensuring sufficient share reserves for inducement and incentive grants.
- No immediate cash outlay, preserving liquidity while compensating employees.
- Potential dilution of up to 825,000 shares once awards vest and are exercised.
- Equity overhang increases, which can pressure per-share metrics if future grants accelerate.
Insights
TL;DR: Routine S-8 adds 825k shares; modest dilution, preserves hiring and retention flexibility.
The filing is procedural, registering roughly 825k new shares (�1% of Rigel’s 86 M share count at 6-Aug-25) for two existing plans. That size will have immaterial EPS impact unless fully issued at once. Nevertheless, equity supply expands the overhang from incentive plans to about 13 M shares, a factor investors track when modeling dilution. From a governance view, the incremental shares were already approved, so no shareholder vote is required. Overall, positive for talent strategy, slightly negative for dilution, net neutral for valuation today.
Rigel Pharmaceuticals ha presentato un modulo Form S-8 per registrare 825.000 azioni ordinarie aggiuntive da emettere nell'ambito dei suoi piani azionari per i dipendenti: 125.000 azioni per il Piano di Incentivazione e 700.000 azioni per il Piano di Incentivi Azionari 2018. La presentazione si basa sull'Istruzione Generale E, incorporando per riferimento precedenti moduli S-8 e coprendo quindi solo le azioni incrementali. Non vengono forniti nuovi bilanci o aggiornamenti aziendali; il documento amplia semplicemente il numero di azioni disponibili per reclutamento, fidelizzazione e compensi generali ai dipendenti. Gli allegati standard includono il parere legale, il consenso alla revisione e i documenti aggiornati dei piani. La registrazione potrebbe causare una diluizione modesta al momento dell'emissione delle azioni, ma consente all'azienda di continuare a utilizzare incentivi azionari senza un impatto immediato in contanti.
Rigel Pharmaceuticals presentó un Formulario S-8 para registrar 825,000 acciones comunes adicionales para emisión bajo sus planes de acciones para empleados: 125,000 acciones para el Plan de Incentivos y 700,000 acciones para el Plan de Incentivos de Capital 2018. La presentación se basa en la Instrucción General E, incorporando formularios S-8 previos por referencia y por lo tanto solo cubre las acciones adicionales. No se proporcionan nuevos estados financieros ni actualizaciones comerciales; el documento simplemente amplía el grupo de acciones disponibles para reclutamiento, retención y compensación general a empleados. Los anexos estándar incluyen la opinión legal, el consentimiento de auditoría y los documentos actualizados del plan. El registro puede resultar en una dilución modesta cuando se emitan las acciones, pero permite a la empresa continuar usando incentivos de capital sin un impacto inmediato en efectivo.
Rigel Pharmaceuticals� 직원 주식 계획� 따라 발행� 추가 보통� 825,000�� 등록하기 위해 Form S-8� 제출했습니다: 유인 계획� 125,000�, 2018� 주식 인센티브 계획� 700,000주입니다. � 제출은 일반 지� E� 기반으로 하며 이전 S-8� 참조� 포함하여 증분 주식만을 다룹니다. 새로� 재무제표� 사업 업데이트� 제공되지 않으�, 단지 직원 채용, 유지 � 일반 보상 목적으로 사용 가능한 주식 풀� 확장하는 내용입니�. 표준 부� 서류에는 법률 의견�, 감사 동의� � 업데이트� 계획 문서가 포함됩니�. 등록은 주식 발행 � 다소 희석 효과� 초래� � 있지�, 회사가 즉각적인 현금 영향 없이 주식 인센티브� 계속 사용� � 있게 합니�.
Rigel Pharmaceuticals a déposé un formulaire S-8 pour enregistrer 825 000 actions ordinaires supplémentaires à émettre dans le cadre de ses plans d'actionnariat salarié : 125 000 actions pour le Plan d'Incitation et 700 000 actions pour le Plan d'Incitation en Actions 2018. Le dépôt s'appuie sur l'Instruction Générale E, incorporant par référence les précédents formulaires S-8 et couvre donc uniquement les actions supplémentaires. Aucun nouvel état financier ou mise à jour commerciale n'est fourni ; le document élargit simplement le nombre d'actions disponibles pour le recrutement, la rétention et la rémunération générale des employés. Les annexes standard incluent l'avis juridique, le consentement d'audit et les documents de plan mis à jour. L'enregistrement peut entraîner une dilution modérée lors de l'émission des actions, mais permet à l'entreprise de continuer à utiliser des incitations en actions sans impact immédiat sur la trésorerie.
Rigel Pharmaceuticals reichte ein Formular S-8 ein, um 825.000 zusätzliche Stammaktien zur Ausgabe im Rahmen seiner Mitarbeiterbeteiligungspläne zu registrieren: 125.000 Aktien für den Anreizplan und 700.000 Aktien für den Aktienanreizplan 2018. Die Einreichung stützt sich auf die Allgemeine Anweisung E, die frühere S-8-Formulare durch Verweis einbezieht und daher nur die zusätzlichen Aktien abdeckt. Es werden keine neuen Finanzberichte oder Geschäftsaktualisierungen bereitgestellt; das Dokument erweitert lediglich den Aktienpool, der für Rekrutierung, Bindung und allgemeine Mitarbeitervergütung zur Verfügung steht. Standardmäßig enthaltene Anlagen sind die Rechtsmeinung, die Prüfungszustimmung und aktualisierte Planunterlagen. Die Registrierung kann bei Ausgabe der Aktien zu einer moderaten Verwässerung führen, ermöglicht dem Unternehmen jedoch, weiterhin Aktienanreize ohne unmittelbare Liquiditätsauswirkungen zu nutzen.
1.
|
Q2 2025 Results
|

adjusted EBITDA of $351 million and adjusted diluted EPS of $0.09
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
||||||
$ millions
|
% of Sales
|
$ millions
|
% of Sales
|
$ millions
|
% of Sales
|
$ millions
|
% of Sales
|
$ millions
|
% of Sales
|
Sales
|
1,832
|
-
|
1,752
|
-
|
3,599
|
-
|
3,487
|
-
|
6,841
|
-
|
Gross profit
|
554
|
30
|
568
|
32
|
1,114
|
31
|
1,125
|
32
|
2,256
|
33
|
Operating income
|
181
|
10
|
211
|
12
|
366
|
10
|
414
|
12
|
775
|
11
|
Adjusted operating income (1)
|
201
|
11
|
225
|
13
|
409
|
11
|
440
|
13
|
873
|
13
|
Net income attributable to the Company's shareholders
|
93
|
5
|
115
|
7
|
184
|
5
|
224
|
6
|
407
|
6
|
Adjusted net income attributable to the Company’s shareholders (1)
|
110
|
6
|
126
|
7
|
220
|
6
|
244
|
7
|
484
|
7
|
Diluted earnings per share (in dollars)
|
0.07
|
-
|
0.09
|
-
|
0.14
|
-
|
0.17
|
-
|
0.32
|
-
|
Diluted adjusted earnings per share (in dollars) (2)
|
0.09
|
-
|
0.10
|
-
|
0.17
|
-
|
0.19
|
-
|
0.38
|
-
|
Adjusted EBITDA (2)
|
351
|
19
|
377
|
22
|
710
|
20
|
739
|
21
|
1,469
|
21
|
Cash flows from operating activities (3)
|
269
|
-
|
316
|
-
|
434
|
-
|
608
|
-
|
1,468
|
-
|
Purchases of property, plant and equipment and intangible assets (3)
|
202
|
-
|
142
|
-
|
392
|
-
|
287
|
-
|
713
|
-
|
(1) |
See “Adjustments to Reported Operating and Net income (non-GAAP)” below.
|
(2) |
See "Adjusted EBITDA and Diluted Adjusted Earnings Per Share for the periods of activity" below.
|
(3) |
See “Condensed consolidated statements of cash flows (unaudited)” in the accompanying financial statements.
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Operating income
|
181
|
211
|
366
|
414
|
775
|
Charges related to the security situation in Israel (1)
|
15
|
14
|
25
|
26
|
57
|
Impairment and write-off of assets and provision for site closure (2)
|
5
|
-
|
5
|
-
|
35
|
Fire incident at Ashdod Port (3)
|
-
|
-
|
4
|
-
|
-
|
Provision for early retirement (4)
|
-
|
-
|
9
|
-
|
4
|
Legal proceedings (5)
|
-
|
-
|
-
|
-
|
2
|
Total adjustments to operating income
|
20
|
14
|
43
|
26
|
98
|
Adjusted operating income
|
201
|
225
|
409
|
440
|
873
|
Net income attributable to the shareholders of the Company
|
93
|
115
|
184
|
224
|
407
|
Total adjustments to operating income
|
20
|
14
|
43
|
26
|
98
|
Total tax adjustments (6)
|
(3)
|
(3)
|
(7)
|
(6)
|
(21)
|
Total adjusted net income - shareholders of the Company
|
110
|
126
|
220
|
244
|
484
|
(1) |
For 2025 and 2024, reflects charges relating to the ongoing security situation in Israel.
|
(2) |
For 2025, reflects a write-off of two portfolio companies due to failed business continuity and funding. For 2024, reflects mainly a write-off of assets
resulting from the closure of small sites in Israel and Turkey, as well as an impairment of assets due to a regulatory decision that mandated the cessation of a certain project.
|
(3) |
For 2025, reflects expenses related to a fire incident at Ashdod Port.
|
(4) |
For 2025 and 2024, reflects provisions for early retirement due to restructuring at certain sites, as part of the Company’s global efficiency plan.
|
(5) |
For 2024, reflects reimbursement of arbitration costs associated with the Ethiopian potash project.
|
(6) |
For 2025 and 2024, reflects the tax impact of adjustments made to operating income.
|
4 ICL Group Limited Q2 2025 Results
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Net income
|
108
|
130
|
214
|
256
|
464
|
Financing expenses, net
|
13
|
33
|
50
|
68
|
140
|
Taxes on income
|
60
|
48
|
102
|
90
|
172
|
Less: Share in earnings of equity-accounted investees
|
-
|
-
|
-
|
-
|
(1)
|
Operating income
|
181
|
211
|
366
|
414
|
775
|
Depreciation and amortization
|
150
|
152
|
301
|
299
|
596
|
Adjustments (1)
|
20
|
14
|
43
|
26
|
98
|
Total adjusted EBITDA
|
351
|
377
|
710
|
739
|
1,469
|
(1) |
See "Adjustments to Reported Operating and Net income (non-GAAP)" above.
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Net income attributable to the Company's shareholders
|
93
|
115
|
184
|
224
|
407
|
Adjustments (1)
|
20
|
14
|
43
|
26
|
98
|
Total tax adjustments
|
(3)
|
(3)
|
(7)
|
(6)
|
(21)
|
Adjusted net income - shareholders of the Company
|
110
|
126
|
220
|
244
|
484
|
Weighted-average number of diluted ordinary shares outstanding
(in thousands) |
1,292,096
|
1,290,158
|
1,291,450
|
1,289,977
|
1,290,039
|
Diluted adjusted earnings per share
(in dollars) (2) |
0.09
|
0.10
|
0.17
|
0.19
|
0.38
|
(1) |
See "Adjustments to Reported Operating and Net income (non-GAAP)" above.
|
(2) |
The diluted adjusted earnings per share are calculated as follows: dividing the adjusted net income attributable to the shareholders of the Company by the
weighted-average number of diluted ordinary shares outstanding (in thousands).
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
Q2 2024 figures
|
1,752
|
(1,541)
|
211
|
|
Total adjustments Q2 2024*
|
-
|
14
|
14
|
|
Adjusted Q2 2024 figures
|
1,752
|
(1,527)
|
225
|
|
Quantity
|
(34)
|
14
|
(20)
|
![]() |
Price
|
94
|
-
|
94
|
![]() |
Exchange rates
|
20
|
(19)
|
1
|
![]() |
Raw materials
|
-
|
(37)
|
(37)
|
![]() |
Energy
|
-
|
2
|
2
|
![]() |
Transportation
|
-
|
9
|
9
|
![]() |
Operating and other expenses
|
-
|
(73)
|
(73)
|
![]() |
Adjusted Q2 2025 figures
|
1,832
|
(1,631)
|
201
|
|
Total adjustments Q2 2025*
|
-
|
(20)
|
(20)
|
|
Q2 2025 figures
|
1,832
|
(1,651)
|
181
|
- |
Quantity – The negative impact on operating income was primarily due to lower sales volumes of potash, FertilizerpluS products and bromine-based flame retardants. This was
partially offset by higher sales volumes of specialty agriculture products, clear brine fluids, phosphorus-based flame retardants and phosphate fertilizers.
|
- |
Price – The positive impact on operating income was primarily driven by a $33 year-over-year increase in the potash price (CIF) per tonne, along with higher selling prices of phosphate fertilizers, specialty agriculture products and
phosphorus-based flame retardants. This was partially offset by lower selling prices of food specialties and white phosphoric acid (WPA).
|
- |
Exchange rates – The favorable impact on operating income was due to a positive impact on sales resulting mainly from the appreciation of the average exchange rate of the euro and the British pound against the US dollar,
which outweighed their negative impact on operational costs.
|
- |
Raw materials – The negative impact on operating income was primarily due to higher cost of sulphur and commodity fertilizers, partially offset by lower cost of raw materials used in the production of industrial solutions
products.
|
- |
Transportation – The positive impact on operating income was primarily due to reduced marine transportation costs.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational costs.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
YTD 2024 figures
|
3,487
|
(3,073)
|
414
|
|
Total adjustments YTD 2024*
|
-
|
26
|
26
|
|
Adjusted YTD 2024 figures
|
3,487
|
(3,047)
|
440
|
|
Quantity
|
55
|
(51)
|
4
|
![]() |
Price
|
73
|
-
|
73
|
![]() |
Exchange rates
|
(16)
|
14
|
(2)
|
![]() |
Raw materials
|
-
|
(25)
|
(25)
|
![]() |
Energy
|
-
|
(1)
|
(1)
|
![]() |
Transportation
|
-
|
26
|
26
|
![]() |
Operating and other expenses
|
-
|
(106)
|
(106)
|
![]() |
Adjusted YTD 2025 figures
|
3,599
|
(3,190)
|
409
|
|
Total adjustments YTD 2025*
|
-
|
(43)
|
(43)
|
|
YTD 2025 figures
|
3,599
|
(3,233)
|
366
|
- |
Quantity – The positive impact on operating income was primarily related to an increase in sales volumes of phosphate fertilizers, specialty agriculture products, phosphorus-based flame retardants, WPA, industrial salts and food
specialties. This was partially offset by lower sales volumes of FertilizerpluS products, potash and bromine-based flame retardants.
|
- |
Price – The positive impact on operating income was primarily driven by a $6 year-over-year increase in the price of potash (CIF) per tonne, along with an increase in selling prices of phosphate fertilizers, specialty agriculture
products and FertilizerpluS products. This impact was partially offset by lower selling prices of WPA, food specialties and industrial salts.
|
- |
Exchange rates – The unfavorable impact on operating income was mainly due to the appreciation of the average exchange rate of the euro and the Israeli shekel against the US dollar, partially offset by the depreciation of
the average exchange rate of the Brazilian real against the US dollar.
|
- |
Raw materials – The negative impact on operating income was primarily due to higher costs of sulphur and commodity fertilizers. This impact was partially offset by lower costs for raw materials used in the production of
industrial solutions products and ammonia.
|
- |
Transportation – The positive impact on operating income was due to reduced marine and inland transportation costs.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational costs.
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Segment Sales
|
319
|
315
|
663
|
650
|
1,239
|
Sales to external customers
|
315
|
309
|
653
|
640
|
1,220
|
Sales to internal customers
|
4
|
6
|
10
|
10
|
19
|
Segment Operating Income
|
54
|
60
|
116
|
119
|
224
|
Depreciation and amortization
|
15
|
14
|
29
|
27
|
57
|
Segment EBITDA
|
69
|
74
|
145
|
146
|
281
|
Capital expenditures
|
16
|
19
|
34
|
35
|
94
|
• |
Elemental bromine: Sales declined slightly year-over-year, with higher prices helping to partially offset lower volumes, mainly driven by continued subdued
demand in the bromine-based flame retardants market.
|
• |
Flame retardants: Sales of bromine-based products decreased year-over-year, primarily due to lower volumes amid continued weak demand, especially in the
construction sector. Higher prices helped to partially offset the decrease. Phosphorus-based sales increased year-over-year, supported by both higher volumes and prices, following the imposition of duties on Chinese imports of tris
(2-chloro-1-methylethyl) phosphate (TCPP), especially in the US.
|
• |
Clear brine fluids: Sales increased year-over-year, primarily due to higher volumes in North America, which enabled ICL to maintain its leading position in this market.
|
• |
Specialty minerals: Sales remained stable year-over-year, as demand across end-markets held steady.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
Q2 2024 figures
|
315
|
(255)
|
60
|
|
Quantity
|
(19)
|
13
|
(6)
|
![]() |
Price
|
19
|
-
|
19
|
![]() |
Exchange rates
|
4
|
(4)
|
-
|
![]() |
Raw materials
|
-
|
2
|
2
|
![]() |
Energy
|
-
|
(1)
|
(1)
|
![]() |
Transportation
|
-
|
(3)
|
(3)
|
![]() |
Operating and other expenses
|
-
|
(17)
|
(17)
|
![]() |
Q2 2025 figures
|
319
|
(265)
|
54
|
- |
Quantity – The negative impact on operating income was primarily driven by lower sales volumes of bromine-based flame retardants and elemental bromine, partially offset by increased sales volumes of clear brine fluids and
phosphorus-based flame retardants.
|
- |
Price – The positive impact on operating income was mainly attributable to higher selling prices of elemental bromine, bromine- and phosphorus-based flame retardants, as well as specialty minerals.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher operational expenses.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
YTD 2024 figures
|
650
|
(531)
|
119
|
|
Quantity
|
(2)
|
-
|
(2)
|
![]() |
Price
|
14
|
-
|
14
|
![]() |
Exchange rates
|
1
|
(2)
|
(1)
|
![]() |
Raw materials
|
-
|
6
|
6
|
![]() |
Energy
|
-
|
(1)
|
(1)
|
![]() |
Transportation
|
-
|
(5)
|
(5)
|
![]() |
Operating and other expenses
|
-
|
(14)
|
(14)
|
![]() |
YTD 2025 figures
|
663
|
(547)
|
116
|
- |
Price – The positive impact on operating income was primarily related to higher selling prices of phosphorus-based flame retardants, specialty minerals and elemental bromine.
|
- |
Raw materials – The positive impact on operating income was driven by decreased raw materials costs.
|
- |
Transportation – The negative impact on operating income was due to an increase in marine and inland transportation costs.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational expenses.
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Segment Sales
|
383
|
422
|
788
|
845
|
1,656
|
Potash sales to external customers
|
297
|
324
|
602
|
631
|
1,237
|
Potash sales to internal customers
|
13
|
17
|
35
|
49
|
95
|
Other and eliminations (1)
|
73
|
81
|
151
|
165
|
324
|
Gross Profit
|
133
|
157
|
269
|
326
|
650
|
Segment Operating Income
|
52
|
60
|
108
|
122
|
250
|
Depreciation and amortization
|
63
|
58
|
125
|
120
|
242
|
Segment EBITDA
|
115
|
118
|
233
|
242
|
492
|
Capital expenditures
|
89
|
63
|
153
|
129
|
332
|
Potash price - CIF ($ per tonne)
|
333
|
300
|
316
|
310
|
299
|
(1) |
Primarily includes salt produced in Spain, metal magnesium-based products, chlorine and sales of surplus electricity produced by ICL’s power plant at the Dead
Sea in Israel.
|
• |
ICL's potash price (CIF) per tonne was $333 in the second quarter, reflecting an 11% increase compared to both the first quarter and year-over-year.
|
• |
The Grain Price Index declined by 3.3% in the second quarter of 2025, driven by decreases in wheat (6.5%), rice (4.6%) and corn (2%) prices. However, soy prices
moved 3.3% higher through the quarter.
|
• |
The WASDE (World Agricultural Supply and Demand Estimates) report, published by the USDA in July 2025, showed a continued decrease in the expected ratio of
global inventories of grains to consumption to 25.7% for the 2025/26 agriculture year, compared to 26.5% for the 2024/25 agriculture year and 28.2% for the 2023/24 agriculture year.
|
• |
In June 2025, ICL reached an agreement with IPL, a long-term customer in India, to supply an aggregate of 400,000 mt of potash, with an option for additional
100,000 mt, at a price of $349 per tonne, aligned with the current market price in India. This agreement falls under the five-year supply agreement with IPL for the years 2022-2027, signed in March 2022.
|
• |
In June 2025, as part of ICL's 2025-2027 Chinese framework agreements, ICL signed contracts with its Chinese customers to supply 750,000 mt of potash with a
mutual option for an additional 340,000 mt, at a price of $346 per tonne, which aligns with recent contract settlements in China.
|
Average prices
|
4-6/2025
|
4-6/2024
|
VS Q2 2024
|
1-3/2025
|
VS Q1 2025
|
Granular potash – Brazil
|
CFR spot
($ per tonne)
|
357
|
311
|
14.8%
|
321
|
11.2%
|
Granular potash – Northwest Europe
|
CIF spot/contract
(€ per tonne)
|
354
|
348
|
1.7%
|
338
|
4.7%
|
Standard potash – Southeast Asia
|
CFR spot
($ per tonne)
|
343
|
292
|
17.5%
|
307
|
11.7%
|
Potash imports
|
||||||
To Brazil
|
million tonnes
|
4.1
|
4.1
|
0.0%
|
2.8
|
46.4%
|
To China
|
million tonnes
|
2.8
|
2.6
|
7.7%
|
3.6
|
(22.2)%
|
To India
|
million tonnes
|
0.3
|
0.9
|
(66.7)%
|
0.8
|
(62.5)%
|
Thousands of tonnes
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
Production
|
957
|
1,108
|
2,019
|
2,238
|
4,502
|
Total sales (including internal sales)
|
971
|
1,153
|
2,074
|
2,237
|
4,556
|
Closing inventory
|
174
|
285
|
174
|
285
|
229
|
- |
Production – Production decreased by 151 thousand tonnes year-over-year, mainly due to operational challenges and war-related issues at the Dead Sea.
|
- |
Sales – The quantity of potash sold decreased by 182 thousand tonnes year-over-year, mainly due to reduced production, which led to lower sales volumes particularly in China, Brazil and the US.
|
- |
Production – Production decreased by 219 thousand tonnes year-over-year, mainly due to operational challenges and war-related issues.
|
- |
Sales – The quantity of potash sold decreased by 163 thousand tonnes year-over-year, mainly due to reduced production, which led to lower sales volumes particularly in China and the US.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
Q2 2024 figures
|
422
|
(362)
|
60
|
|
Quantity
|
(65)
|
46
|
(19)
|
![]() |
Price
|
19
|
-
|
19
|
![]() |
Exchange rates
|
7
|
(6)
|
1
|
![]() |
Transportation
|
-
|
7
|
7
|
![]() |
Operating and other expenses
|
-
|
(16)
|
(16)
|
![]() |
Q2 2025 figures
|
383
|
(331)
|
52
|
- |
Quantity – The negative impact on operating income was primarily due to lower potash sales volumes in China, Brazil and the US, partially offset by higher potash sales volumes in Europe and India.
|
- |
Price – The positive impact on operating income was primarily driven by a $33 year-over-year increase in the potash price (CIF) per tonne, partially offset by lower prices of other products.
|
- |
Exchange rates – The favorable impact on operating income was mainly due to the appreciation of the average exchange rate of the British pound against the US dollar, partially offset by the appreciation of the average
exchange rate of the euro against the US dollar.
|
- |
Transportation – The positive impact on operating income was primarily due to reduced marine transportation costs, primarily to Brazil and China.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational costs.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
YTD 2024 figures
|
845
|
(723)
|
122
|
|
Quantity
|
(57)
|
45
|
(12)
|
![]() |
Price
|
(4)
|
-
|
(4)
|
![]() |
Exchange rates
|
4
|
(4)
|
-
|
![]() |
Raw materials
|
-
|
1
|
1
|
![]() |
Energy
|
-
|
(4)
|
(4)
|
![]() |
Transportation
|
-
|
21
|
21
|
![]() |
Operating and other expenses
|
-
|
(16)
|
(16)
|
![]() |
YTD 2025 figures
|
788
|
(680)
|
108
|
- |
Quantity – The negative impact on operating income was primarily related to a decrease in sales volumes of magnesium, as well as a decrease in potash sales volumes in China and the US, partially offset by higher potash sales volumes
mainly in Europe and Brazil.
|
- |
Price – The negative impact on operating income was mainly due to a decline in the prices of several products, partially offset by a relatively small increase in the potash price (CIF) year-over-year.
|
- |
Transportation – The positive impact on operating income was primarily due to reduced inland and marine transportation costs, primarily to Brazil, China and the US.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational costs.
|
4-6/2025 (1)
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Segment Sales
|
637
|
572
|
1,210
|
1,131
|
2,215
|
Sales to external customers
|
589
|
528
|
1,125
|
1,045
|
2,049
|
Sales to internal customers
|
48
|
44
|
85
|
86
|
166
|
Segment Operating Income
|
90
|
93
|
181
|
177
|
358
|
Depreciation and amortization
|
44
|
53
|
92
|
100
|
191
|
Segment EBITDA
|
134
|
146
|
273
|
277
|
549
|
Capital expenditures
|
84
|
71
|
155
|
123
|
340
|
(1) |
For Q2 2025, Phosphate Specialties accounted for $336 million of segment sales, $39 million of operating income, $12 million of D&A and $51 million of
EBITDA, while Phosphate Commodities accounted for $301 million of segment sales, $51 million of operating income, $32 million of D&A and represented $83 million of EBITDA.
|
• |
Phosphate prices strengthened significantly during the second quarter of 2025, supported by favorable weather conditions that spurred firm demand across most
key markets. Additional upward pressure stemmed from reduced Chinese DAP and MAP availability, perceived risks and opportunities related to new tariffs, and notable foreign exchange fluctuations. Key fertilizer benchmarks averaged 18%
higher quarter-over-quarter and 31% higher year-over-year.
|
• |
Developments in key markets are described below:
|
- |
In China, DAP and MAP exports remained limited due to trade policy restrictions in 2025. During the first five months of the year, total exports fell below 0.2
million mt, compared to 1.6 million mt in 2024. Instead, these products were allocated primarily to domestic farmers, which helped to maintain stable local prices during the second quarter, which remained unchanged from the end of the
prior quarter.
|
- |
In the US, corn planting reached 95.2 million acres, approximately 5% higher year-over-year, supporting fertilizer demand. As a result, the DAP FOB NOLA rose by
$114/mt to $794/mt at the end of the period.
|
- |
In Latin America, fertilizer importers and distributors have been anticipating a strong agricultural year, driven by expectations of increased export
opportunities stemming from US-China trade tensions. These expectations have led to a continued buildup of inventory levels of fertilizers, as well as progressively higher prices. In Brazil, MAP and Triple Super Phosphate (TSP)
benchmarks ended the second quarter at $755/mt and $595/mt, respectively, representing an increase of $140/mt and $145/mt, respectively, year-over-year. While sentiment remained firm, the sharp price increases resulted in cautious
purchasing behavior among farmers and growing interest in more affordable alternatives. For instance, Single Super Phosphate (SSP) imports were estimated at 1.7 million mt in the first half of 2025, compared to 1.2 million mt and 1.5
million mt during the same period in 2023 and 2024.
|
• |
Indian phosphoric acid prices are negotiated quarterly. The price for the third quarter was agreed at $1,258/mt P2O5, an increase of $105
compared to the second quarter of 2025.
|
• |
Sulphur FOB Middle East ended the second quarter at $270/mt. The benchmark is $10/mt lower than at the end of the first quarter, however, it remains elevated
compared to historical norms, with an $188/mt increase from prevailing levels at the end of the second quarter of 2024. Increases earlier in the year were driven by firm demand from the metals sector, constrained supply, the need to
replenish Chinese inventories, and market concerns regarding the potential impact of US tariffs.
|
• |
Sales of white phosphoric acid (WPA) increased slightly year-over-year, as volume growth across all major regions offset lower prices.
|
• |
Sales of industrial salts increased year-over-year, supported by continued volume growth, particularly in North America and China, which offset lower prices.
|
• |
Sales of food specialties remained flat compared to the previous year, as higher volumes were fully offset by a decline in market prices, which was primarily
driven by reduced input costs.
|
• |
Sales of battery materials in China increased year-over-year, reflecting both higher volumes and improved pricing.
|
Average prices
|
$ per tonne
|
4-6/2025
|
4-6/2024
|
VS Q2 2024
|
1-3/2025
|
VS Q1 2025
|
DAP
|
CFR India Bulk Spot
|
723
|
527
|
37%
|
635
|
14%
|
TSP
|
CFR Brazil Bulk Spot
|
564
|
425
|
33%
|
500
|
13%
|
SSP
|
CPT Brazil inland 18-20% P2O5 Bulk Spot
|
312
|
281
|
11%
|
281
|
11%
|
Sulphur
|
Bulk FOB Adnoc monthly Bulk contract
|
286
|
84
|
240%
|
183
|
56%
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
Q2 2024 figures
|
572
|
(479)
|
93
|
|
Quantity
|
34
|
(26)
|
8
|
![]() |
Price
|
23
|
-
|
23
|
![]() |
Exchange rates
|
8
|
(4)
|
4
|
![]() |
Raw materials
|
-
|
(23)
|
(23)
|
![]() |
Energy
|
-
|
(2)
|
(2)
|
![]() |
Transportation
|
-
|
6
|
6
|
![]() |
Operating and other expenses
|
-
|
(19)
|
(19)
|
![]() |
Q2 2025 figures
|
637
|
(547)
|
90
|
- |
Quantity – The positive impact on operating income was due to higher sales volumes of phosphate fertilizers, food specialties, white phosphoric acid, industrial salts as well as MAP used as a raw material for energy storage solutions.
|
- |
Price – The positive impact on operating income was primarily related to higher selling prices of phosphate fertilizers. This was partially offset by lower selling prices of food specialties, white phosphoric acid, and industrial
salts.
|
- |
Raw materials – The negative impact on operating income was primarily driven by higher sulphur costs, partially offset by lower ammonia costs.
|
- |
Transportation – The positive impact on operating income was due to reduced marine and inland transportation costs.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational expenses.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
YTD 2024 figures
|
1,131
|
(954)
|
177
|
|
Quantity
|
59
|
(37)
|
22
|
![]() |
Price
|
17
|
-
|
17
|
![]() |
Exchange rates
|
3
|
1
|
4
|
![]() |
Raw materials
|
-
|
(14)
|
(14)
|
![]() |
Energy
|
-
|
(2)
|
(2)
|
![]() |
Transportation
|
-
|
9
|
9
|
![]() |
Operating and other expenses
|
-
|
(32)
|
(32)
|
![]() |
YTD 2025 figures
|
1,210
|
(1,029)
|
181
|
- |
Quantity – The positive impact on operating income was due to higher sales volumes of phosphate fertilizers, white phosphoric acid, industrial salts and food specialties.
|
- |
Price – The positive impact on operating income primarily related to higher selling prices of phosphate fertilizers and MAP used as a raw material for energy storage solutions. This was partially offset by lower selling prices of
white phosphoric acid, food specialties and industrial salts.
|
- |
Raw materials – The negative impact on operating income was due to higher costs of sulphur. This was partially offset by lower costs of ammonia.
|
- |
Transportation – The positive impact on operating income was due to reduced marine and inland transportation costs.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational expenses.
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Segment Sales
|
540
|
494
|
1,035
|
973
|
1,950
|
Sales to external customers
|
534
|
489
|
1,025
|
963
|
1,932
|
Sales to internal customers
|
6
|
5
|
10
|
10
|
18
|
Segment Operating Income
|
35
|
25
|
63
|
48
|
128
|
Depreciation and amortization
|
21
|
20
|
40
|
39
|
74
|
Segment EBITDA
|
56
|
45
|
103
|
87
|
202
|
Capital expenditures
|
16
|
19
|
35
|
34
|
98
|
• |
Specialty Agriculture (SA): Sales increased year-over-year due to higher volumes- -– mainly in the US, Europe, and India, favorable pricing, particularly for micronutrients in Brazil, and the July 2024
acquisition of Custom Ag Formulators (CAF). This increase was partially offset by fluctuations in the Brazilian real exchange rate.
|
• |
Turf and Ornamental (T&O): Sales increased year-over-year, driven mainly by growth in Europe. The increase was primarily attributable to higher prices, especially in Ornamental Horticulture, and the
acquisition of GreenBest.
|
• |
FertilizerpluS: Sales decreased year-over-year, mainly due to lower sales volumes in Europe. This decrease was partially offset by higher selling prices of PK
Plus in Europe and granular Polysulphate in the US, as well as increased volumes in India.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
Q2 2024 figures
|
494
|
(469)
|
25
|
|
Quantity
|
9
|
(4)
|
5
|
![]() |
Price
|
36
|
-
|
36
|
![]() |
Exchange rates
|
1
|
(1)
|
-
|
![]() |
Raw materials
|
-
|
(23)
|
(23)
|
![]() |
Energy
|
-
|
5
|
5
|
![]() |
Transportation
|
-
|
(1)
|
(1)
|
![]() |
Operating and other expenses
|
-
|
(12)
|
(12)
|
![]() |
Q2 2025 figures
|
540
|
(505)
|
35
|
- |
Quantity – The positive impact on operating income was primarily related to higher sales volumes of specialty agriculture products, partially offset by lower sales volumes of FertilizerpluS products.
|
- |
Price – The positive impact on operating income was due to higher selling prices of specialty agriculture and FertilizerpluS products.
|
- |
Raw materials – The negative impact on operating income was primarily related to higher costs of commodity fertilizers, sulphur and nitrogen.
|
- |
Energy – The positive impact on operating income was due to decreased electricity and gas prices.
|
- |
Operating and other expenses – The negative impact on operating income was primarily related to higher maintenance and operational costs.
|
Sales
|
Expenses
|
Operating
income
|
||
$ millions
|
YTD 2024 figures
|
973
|
(925)
|
48
|
|
Quantity
|
36
|
(27)
|
9
|
![]() |
Price
|
50
|
-
|
50
|
![]() |
Exchange rates
|
(24)
|
22
|
(2)
|
![]() |
Raw materials
|
-
|
(28)
|
(28)
|
![]() |
Energy
|
-
|
6
|
6
|
![]() |
Transportation
|
-
|
1
|
1
|
![]() |
Operating and other expenses
|
-
|
(21)
|
(21)
|
![]() |
YTD 2025 figures
|
1,035
|
(972)
|
63
|
- |
Quantity – The positive impact on operating income was primarily related to higher sales volumes of specialty agriculture products, partially offset by lower sales volumes of FertilizerpluS products.
|
- |
Price – The positive impact on operating income was due to higher selling prices of specialty agriculture and FertilizerpluS products, as well as turf and ornamental products.
|
- |
Exchange rate – The unfavorable impact on operating income was mainly due to the depreciation of the average exchange rate of the Brazilian real against the US dollar, partially offset by the appreciation of the average
exchange rate of the euro against the US dollar.
|
- |
Raw materials – The negative impact on operating income was primarily related to higher costs of commodity fertilizers, sulphur and nitrogen.
|
- |
Energy – The positive impact on operating income was primarily due to decreased electricity and gas prices.
|
- |
Operating and other expenses – The
negative impact on operating income was primarily related to higher maintenance and operational costs.
|

June 30,
2025
|
June 30,
2024
|
December 31,
2024
|
|
$ millions
|
$ millions
|
$ millions
|
Current assets
|
|||
Cash and cash equivalents
|
582
|
287
|
327
|
Short-term investments and deposits
|
119
|
109
|
115
|
Trade receivables
|
1,431
|
1,429
|
1,260
|
Inventories
|
1,690
|
1,544
|
1,626
|
Prepaid expenses and other receivables
|
413
|
298
|
258
|
Total current assets
|
4,235
|
3,667
|
3,586
|
Non-current assets
|
|||
Deferred tax assets
|
172
|
147
|
143
|
Property, plant and equipment
|
6,701
|
6,285
|
6,462
|
Intangible assets
|
941
|
857
|
869
|
Other non-current assets
|
326
|
249
|
261
|
Total non-current assets
|
8,140
|
7,538
|
7,735
|
Total assets
|
12,375
|
11,205
|
11,321
|
Current liabilities
|
|||
Short-term debt
|
365
|
577
|
384
|
Trade payables
|
1,082
|
834
|
1,002
|
Provisions
|
59
|
49
|
63
|
Other payables
|
920
|
802
|
879
|
Total current liabilities
|
2,426
|
2,262
|
2,328
|
Non-current liabilities
|
|||
Long-term debt and debentures
|
2,550
|
1,850
|
1,909
|
Deferred tax liabilities
|
477
|
500
|
481
|
Long-term employee liabilities
|
365
|
330
|
331
|
Long-term provisions and accruals
|
244
|
218
|
230
|
Other
|
45
|
61
|
55
|
Total non-current liabilities
|
3,681
|
2,959
|
3,006
|
Total liabilities
|
6,107
|
5,221
|
5,334
|
Equity
|
|||
Total shareholders’ equity
|
6,014
|
5,746
|
5,724
|
Non-controlling interests
|
254
|
238
|
263
|
Total equity
|
6,268
|
5,984
|
5,987
|
Total liabilities and equity
|
12,375
|
11,205
|
11,321
|
For the three-month period
ended June 30
|
For the six-month period
ended June 30
|
For the year ended December 31
|
|||
2025
|
2024
|
2025
|
2024
|
2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Sales
|
1,832
|
1,752
|
3,599
|
3,487
|
6,841
|
Cost of sales
|
1,278
|
1,184
|
2,485
|
2,362
|
4,585
|
Gross profit
|
554
|
568
|
1,114
|
1,125
|
2,256
|
Selling, transport and marketing expenses
|
274
|
280
|
542
|
553
|
1,114
|
General and administrative expenses
|
72
|
64
|
149
|
128
|
259
|
Research and development expenses
|
19
|
14
|
37
|
31
|
69
|
Other expenses
|
11
|
2
|
27
|
5
|
60
|
Other income
|
(3)
|
(3)
|
(7)
|
(6)
|
(21)
|
Operating income
|
181
|
211
|
366
|
414
|
775
|
Finance expenses
|
98
|
59
|
160
|
119
|
181
|
Finance income
|
(85)
|
(26)
|
(110)
|
(51)
|
(41)
|
Finance expenses, net
|
13
|
33
|
50
|
68
|
140
|
Share in earnings of equity-accounted investees
|
-
|
-
|
-
|
-
|
1
|
Income before taxes on income
|
168
|
178
|
316
|
346
|
636
|
Taxes on income
|
60
|
48
|
102
|
90
|
172
|
Net income
|
108
|
130
|
214
|
256
|
464
|
Net income attributable to the non-controlling interests
|
15
|
15
|
30
|
32
|
57
|
Net income attributable to the shareholders of the Company
|
93
|
115
|
184
|
224
|
407
|
Earnings per share attributable to the shareholders of the Company:
|
|||||
Basic earnings per share (in dollars)
|
0.07
|
0.09
|
0.14
|
0.17
|
0.32
|
Diluted earnings per share (in dollars)
|
0.07
|
0.09
|
0.14
|
0.17
|
0.32
|
Weighted-average number of ordinary shares outstanding:
|
|||||
Basic (in thousands)
|
1,290,751
|
1,289,901
|
1,290,603
|
1,289,716
|
1,289,968
|
Diluted (in thousands)
|
1,292,096
|
1,290,158
|
1,291,450
|
1,289,977
|
1,290,039
|
For the three-month
period ended
|
For the six-month
period ended
|
For the year ended
|
|||
June 30, 2025
|
June 30, 2024
|
June 30, 2025
|
June 30, 2024
|
December 31, 2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Net income
|
108
|
130
|
214
|
256
|
464
|
Components of other comprehensive income that will be reclassified subsequently to net income
|
|||||
Foreign currency translation differences
|
108
|
(84)
|
198
|
(142)
|
(247)
|
Change in fair value of cash flow hedges transferred to the statement of income
|
(38)
|
8
|
(34)
|
13
|
10
|
Effective portion of the change in fair value of cash flow hedges
|
66
|
(14)
|
48
|
(19)
|
(2)
|
Tax relating to items that will be reclassified subsequently to net income
|
(6)
|
1
|
(3)
|
1
|
(2)
|
130
|
(89)
|
209
|
(147)
|
(241)
|
|
Components of other comprehensive income that will not be reclassified to net income
|
|||||
Actuarial gains from defined benefit plans
|
2
|
15
|
2
|
13
|
33
|
Tax relating to items that will not be reclassified to net income
|
(1)
|
(3)
|
(1)
|
(3)
|
(8)
|
1
|
12
|
1
|
10
|
25
|
|
Total comprehensive income
|
239
|
53
|
424
|
119
|
248
|
Comprehensive income attributable to the non-controlling interests
|
17
|
13
|
33
|
26
|
51
|
Comprehensive income attributable to the shareholders of the Company
|
222
|
40
|
391
|
93
|
197
|
For the three-month
period ended
|
For the six-month
period ended
|
For the year ended
|
|||
June 30, 2025
|
June 30, 2024
|
June 30, 2025
|
June 30, 2024
|
December 31, 2024
|
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
$ millions
|
Cash flows from operating activities
|
|||||
Net income
|
108
|
130
|
214
|
256
|
464
|
Adjustments for:
|
|||||
Depreciation and amortization
|
150
|
152
|
301
|
299
|
596
|
Fixed assets impairment
|
-
|
-
|
-
|
-
|
14
|
Exchange rate, interest and derivative, net
|
(84)
|
37
|
(40)
|
96
|
152
|
Tax expenses
|
60
|
48
|
102
|
90
|
172
|
Change in provisions
|
7
|
(11)
|
2
|
(53)
|
(50)
|
Other
|
8
|
2
|
11
|
4
|
13
|
141
|
228
|
376
|
436
|
897
|
|
Change in inventories
|
(6)
|
58
|
22
|
109
|
(7)
|
Change in trade receivables
|
119
|
26
|
(83)
|
(115)
|
26
|
Change in trade payables
|
28
|
(55)
|
59
|
(29)
|
104
|
Change in other receivables
|
(4)
|
(14)
|
(19)
|
4
|
39
|
Change in other payables
|
(80)
|
(28)
|
(62)
|
(18)
|
43
|
Net change in operating assets and liabilities
|
57
|
(13)
|
(83)
|
(49)
|
205
|
Income taxes paid, net of refund
|
(37)
|
(29)
|
(73)
|
(35)
|
(98)
|
Net cash provided by operating activities
|
269
|
316
|
434
|
608
|
1,468
|
Cash flows from investing activities
|
|||||
Proceeds (payments) from deposits, net
|
1
|
11
|
(3)
|
61
|
56
|
Purchases of property, plant and equipment and intangible assets
|
(202)
|
(142)
|
(392)
|
(287)
|
(713)
|
Proceeds from divestiture of assets and businesses, net of transaction expenses
|
1
|
3
|
3
|
18
|
19
|
Payments from settlement of derivatives, net
|
(16)
|
-
|
(16)
|
-
|
-
|
Interest received
|
4
|
3
|
7
|
10
|
17
|
Business combinations
|
-
|
-
|
(3)
|
(22)
|
(74)
|
Other
|
-
|
-
|
-
|
-
|
1
|
Net cash used in investing activities
|
(212)
|
(125)
|
(404)
|
(220)
|
(694)
|
Cash flows from financing activities
|
|||||
Dividends paid to the Company's shareholders
|
(55)
|
(59)
|
(107)
|
(120)
|
(251)
|
Receipts of long-term debt
|
683
|
140
|
1,044
|
338
|
889
|
Repayments of long-term debt
|
(138)
|
(226)
|
(535)
|
(612)
|
(1,302)
|
Repayments of short-term debt
|
(206)
|
(18)
|
(97)
|
(1)
|
(1)
|
Interest paid
|
(42)
|
(43)
|
(58)
|
(63)
|
(122)
|
Receipts (payments) from transactions in derivatives
|
(2)
|
-
|
(2)
|
3
|
(2)
|
Dividend paid to the non-controlling interests
|
(42)
|
(57)
|
(42)
|
(57)
|
(57)
|
Net cash provided by (used in) financing activities
|
198
|
(263)
|
203
|
(512)
|
(846)
|
Net change in cash and cash equivalents
|
255
|
(72)
|
233
|
(124)
|
(72)
|
Cash and cash equivalents as of the beginning of the period
|
312
|
363
|
327
|
420
|
420
|
Net effect of currency translation on cash and cash equivalents
|
15
|
(4)
|
22
|
(9)
|
(21)
|
Cash and cash equivalents as of the end of the period
|
582
|
287
|
582
|
287
|
327
|
Attributable to the shareholders of the Company
|
Non-controlling interests
|
Total
equity
|
|||||||
Share
capital
|
Share premium
|
Cumulative translation adjustments
|
Capital reserves
|
Treasury shares,
at cost
|
Retained earnings
|
Total shareholders' equity
|
|||
$ millions
|
For the three-month period ended June 30, 2025
|
|||||||||
Balance as of April 1, 2025
|
549
|
238
|
(637)
|
151
|
(260)
|
5,803
|
5,844
|
279
|
6,123
|
Share-based compensation
|
-
|
2
|
-
|
1
|
-
|
-
|
3
|
-
|
3
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(55)
|
(55)
|
(42)
|
(97)
|
Comprehensive income
|
-
|
-
|
106
|
22
|
-
|
94
|
222
|
17
|
239
|
Balance as of June 30, 2025
|
549
|
240
|
(531)
|
174
|
(260)
|
5,842
|
6,014
|
254
|
6,268
|
Attributable to the shareholders of the Company
|
Non-controlling interests
|
Total
equity
|
|||||||
Share
capital
|
Share premium
|
Cumulative translation adjustments
|
Capital reserves
|
Treasury shares,
at cost
|
Retained earnings
|
Total shareholders' equity
|
|||
$ millions
|
For the three-month period ended June 30, 2024
|
|||||||||
Balance as of April 1, 2024
|
549
|
235
|
(539)
|
148
|
(260)
|
5,629
|
5,762
|
282
|
6,044
|
Share-based compensation
|
-
|
2
|
-
|
1
|
-
|
-
|
3
|
-
|
3
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(59)
|
(59)
|
(57)
|
(116)
|
Comprehensive income
|
-
|
-
|
(82)
|
(5)
|
-
|
127
|
40
|
13
|
53
|
Balance as of June 30, 2024
|
549
|
237
|
(621)
|
144
|
(260)
|
5,697
|
5,746
|
238
|
5,984
|
Attributable to the shareholders of the Company
|
Non-controlling interests
|
Total
equity
|
|||||||
Share
capital
|
Share premium
|
Cumulative translation adjustments
|
Capital reserves
|
Treasury shares,
at cost
|
Retained earnings
|
Total shareholders' equity
|
|||
$ millions
|
For the six-month period ended June 30, 2025
|
|||||||||
Balance as of January 1, 2025
|
549
|
238
|
(726)
|
159
|
(260)
|
5,764
|
5,724
|
263
|
5,987
|
Share-based compensation
|
-
|
2
|
-
|
4
|
-
|
-
|
6
|
-
|
6
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(107)
|
(107)
|
(42)
|
(149)
|
Comprehensive income
|
-
|
-
|
195
|
11
|
-
|
185
|
391
|
33
|
424
|
Balance as of June 30, 2025
|
549
|
240
|
(531)
|
174
|
(260)
|
5,842
|
6,014
|
254
|
6,268
|
Attributable to the shareholders of the Company
|
Non-controlling interests
|
Total
equity
|
|||||||
Share
capital
|
Share premium
|
Cumulative translation adjustments
|
Capital reserves
|
Treasury shares,
at cost
|
Retained earnings
|
Total shareholders' equity
|
|||
$ millions
|
For the six-month period ended June 30, 2024
|
|||||||||
Balance as of January 1, 2024
|
549
|
234
|
(485)
|
147
|
(260)
|
5,583
|
5,768
|
269
|
6,037
|
Share-based compensation
|
-
|
3
|
-
|
2
|
-
|
-
|
5
|
-
|
5
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(120)
|
(120)
|
(57)
|
(177)
|
Comprehensive income
|
-
|
-
|
(136)
|
(5)
|
-
|
234
|
93
|
26
|
119
|
Balance as of June 30, 2024
|
549
|
237
|
(621)
|
144
|
(260)
|
5,697
|
5,746
|
238
|
5,984
|
Attributable to the shareholders of the Company
|
Non-controlling interests
|
Total
equity
|
|||||||
Share
capital
|
Share premium
|
Cumulative translation adjustments
|
Capital reserves
|
Treasury shares,
at cost
|
Retained earnings
|
Total shareholders' equity
|
|||
$ millions
|
For the year ended December 31, 2024
|
|||||||||
Balance as of January 1, 2024
|
549
|
234
|
(485)
|
147
|
(260)
|
5,583
|
5,768
|
269
|
6,037
|
Share-based compensation
|
-
|
4
|
-
|
6
|
-
|
-
|
10
|
-
|
10
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
(251)
|
(251)
|
(57)
|
(308)
|
Comprehensive income
|
-
|
-
|
(241)
|
6
|
-
|
432
|
197
|
51
|
248
|
Balance as of December 31, 2024
|
549
|
238
|
(726)
|
159
|
(260)
|
5,764
|
5,724
|
263
|
5,987
|
A. |
The Reporting Entity
|
B. |
Events during the reporting period
|
A. |
Basis of Preparation
|
B. |
Reclassifications
|
C. |
Amendments to standards and interpretations that have not yet been adopted
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the three-month period ended June 30, 2025
|
|||||||
Sales to external parties
|
315
|
347
|
589
|
534
|
47
|
-
|
1,832
|
Inter-segment sales
|
4
|
36
|
48
|
6
|
-
|
(94)
|
-
|
Total sales
|
319
|
383
|
637
|
540
|
47
|
(94)
|
1,832
|
Cost of Sales
|
214
|
250
|
460
|
398
|
42
|
(86)
|
1,278
|
Segment operating income (loss)
|
54
|
52
|
90
|
35
|
(2)
|
(28)
|
201
|
Other expenses not allocated to the segments
|
(20)
|
||||||
Operating income
|
181
|
||||||
Financing expenses, net
|
(13)
|
||||||
Income before income taxes
|
168
|
||||||
Depreciation and amortization
|
15
|
63
|
44
|
21
|
4
|
3
|
150
|
Capital expenditures
|
16
|
89
|
84
|
16
|
3
|
6
|
214
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the three-month period ended June 30, 2024
|
|||||||
Sales to external parties
|
309
|
381
|
528
|
489
|
45
|
-
|
1,752
|
Inter-segment sales
|
6
|
41
|
44
|
5
|
2
|
(98)
|
-
|
Total sales
|
315
|
422
|
572
|
494
|
47
|
(98)
|
1,752
|
Cost of sales
|
208
|
265
|
389
|
369
|
44
|
(91)
|
1,184
|
Segment operating income (loss)
|
60
|
60
|
93
|
25
|
(4)
|
(9)
|
225
|
Other expenses not allocated to the segments
|
(14)
|
||||||
Operating income
|
211
|
||||||
Financing expenses, net
|
(33)
|
||||||
Income before income taxes
|
178
|
||||||
Depreciation and amortization
|
14
|
58
|
53
|
20
|
4
|
3
|
152
|
Capital expenditures
|
19
|
63
|
71
|
19
|
2
|
6
|
180
|
Capital expenditures as part of business combination
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the six-month period ended June 30, 2025
|
||||||||||||||
Sales to external parties
|
653
|
705
|
1,125
|
1,025
|
91
|
-
|
3,599
|
|||||||
Inter-segment sales
|
10
|
83
|
85
|
10
|
1
|
(189)
|
-
|
|||||||
Total sales
|
663
|
788
|
1,210
|
1,035
|
92
|
(189)
|
3,599
|
|||||||
Cost of Sales
|
442
|
519
|
857
|
762
|
82
|
(177)
|
2,485
|
|||||||
Segment operating income (loss)
|
116
|
108
|
181
|
63
|
(5)
|
(54)
|
409
|
|||||||
Other expenses not allocated to the segments
|
(43)
|
|||||||||||||
Operating income
|
366
|
|||||||||||||
Financing expenses, net
|
(50)
|
|||||||||||||
Income before income taxes
|
316
|
|||||||||||||
Depreciation, amortization and impairment
|
29
|
125
|
92
|
40
|
8
|
7
|
301
|
|||||||
Capital expenditures
|
34
|
153
|
155
|
35
|
4
|
21
|
402
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the six-month period ended June 30, 2024
|
|||||||
Sales to external parties
|
640
|
748
|
1,045
|
963
|
91
|
-
|
3,487
|
Inter-segment sales
|
10
|
97
|
86
|
10
|
2
|
(205)
|
-
|
Total sales
|
650
|
845
|
1,131
|
973
|
93
|
(205)
|
3,487
|
Cost of sales
|
433
|
519
|
780
|
732
|
86
|
(188)
|
2,362
|
Segment operating income (loss)
|
119
|
122
|
177
|
48
|
(7)
|
(19)
|
440
|
Other expenses not allocated to the segments
|
(26)
|
||||||
Operating income
|
414
|
||||||
Financing expenses, net
|
(68)
|
||||||
Income before income taxes
|
346
|
||||||
Depreciation and amortization
|
27
|
120
|
100
|
39
|
8
|
5
|
299
|
Capital expenditures
|
35
|
129
|
123
|
34
|
3
|
11
|
335
|
Capital expenditures as part of business combination
|
-
|
-
|
-
|
35
|
-
|
-
|
35
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2024
|
|||||||
Sales to external parties
|
1,220
|
1,462
|
2,049
|
1,932
|
178
|
-
|
6,841
|
Inter-segment sales
|
19
|
194
|
166
|
18
|
3
|
(400)
|
-
|
Total sales
|
1,239
|
1,656
|
2,215
|
1,950
|
181
|
(400)
|
6,841
|
Cost of sales
|
821
|
1,006
|
1,515
|
1,426
|
175
|
(358)
|
4,585
|
Segment operating income (loss)
|
224
|
250
|
358
|
128
|
(22)
|
(65)
|
873
|
Other expenses not allocated to the segments
|
(98)
|
||||||
Operating income
|
775
|
||||||
Financing expenses, net
|
(140)
|
||||||
Share in earnings of equity-accounted investees
|
1
|
||||||
Income before income taxes
|
636
|
||||||
Depreciation, amortization and impairment
|
57
|
242
|
191
|
74
|
15
|
31
|
610
|
Capital expenditures
|
94
|
332
|
340
|
98
|
8
|
30
|
902
|
Capital expenditures as part of business combination
|
-
|
-
|
-
|
92
|
-
|
-
|
92
|
4-6/2025
|
4-6/2024
|
1-6/2025
|
1-6/2024
|
1-12/2024
|
||||||
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
$
millions
|
% of
sales
|
Brazil
|
367
|
20
|
358
|
20
|
622
|
17
|
568
|
16
|
1,228
|
18
|
USA
|
331
|
18
|
282
|
16
|
649
|
18
|
601
|
17
|
1,176
|
17
|
China
|
259
|
14
|
281
|
16
|
549
|
15
|
536
|
15
|
1,068
|
16
|
United Kingdom
|
88
|
5
|
79
|
5
|
199
|
6
|
181
|
5
|
317
|
5
|
Spain
|
86
|
5
|
79
|
5
|
168
|
5
|
153
|
4
|
301
|
4
|
Israel
|
80
|
4
|
75
|
4
|
146
|
4
|
143
|
4
|
285
|
4
|
Germany
|
76
|
4
|
82
|
5
|
159
|
4
|
174
|
5
|
315
|
5
|
France
|
60
|
3
|
56
|
3
|
133
|
4
|
147
|
4
|
256
|
4
|
India
|
50
|
3
|
36
|
2
|
97
|
3
|
70
|
2
|
197
|
3
|
Austria
|
41
|
2
|
34
|
2
|
76
|
2
|
66
|
2
|
132
|
2
|
All other
|
394
|
22
|
390
|
22
|
801
|
22
|
848
|
26
|
1,566
|
22
|
Total
|
1,832
|
100
|
1,752
|
100
|
3,599
|
100
|
3,487
|
100
|
6,841
|
100
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the three-month period ended June 30, 2025
|
|||||||
Europe
|
101
|
124
|
142
|
196
|
39
|
(28)
|
574
|
Asia
|
91
|
45
|
189
|
79
|
3
|
(8)
|
399
|
South America
|
5
|
127
|
108
|
159
|
-
|
(2)
|
397
|
North America
|
109
|
36
|
154
|
58
|
1
|
-
|
358
|
Rest of the world
|
13
|
51
|
44
|
48
|
4
|
(56)
|
104
|
Total
|
319
|
383
|
637
|
540
|
47
|
(94)
|
1,832
|
Industrial
Products
|
Potash
|
Phosphate
Solutions
|
Growing
Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the three-month period ended June 30, 2024
|
|||||||
Europe
|
109
|
96
|
145
|
182
|
33
|
(31)
|
534
|
Asia
|
109
|
79
|
143
|
76
|
8
|
(7)
|
408
|
South America
|
6
|
138
|
100
|
150
|
-
|
(3)
|
391
|
North America
|
76
|
50
|
140
|
42
|
-
|
(1)
|
307
|
Rest of the world
|
15
|
59
|
44
|
44
|
6
|
(56)
|
112
|
Total
|
315
|
422
|
572
|
494
|
47
|
(98)
|
1,752
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Growing Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the six-month period ended June 30, 2025
|
|||||||
Europe
|
204
|
273
|
278
|
424
|
72
|
(62)
|
1,189
|
Asia
|
209
|
119
|
361
|
144
|
7
|
(14)
|
826
|
South America
|
10
|
213
|
189
|
271
|
-
|
(4)
|
679
|
North America
|
213
|
83
|
295
|
115
|
2
|
(3)
|
705
|
Rest of the world
|
27
|
100
|
87
|
81
|
11
|
(106)
|
200
|
Total
|
663
|
788
|
1,210
|
1,035
|
92
|
(189)
|
3,599
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Growing Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the six-month period ended June 30, 2024
|
|||||||
Europe
|
213
|
265
|
288
|
417
|
64
|
(74)
|
1,173
|
Asia
|
219
|
155
|
303
|
137
|
18
|
(12)
|
820
|
South America
|
10
|
197
|
169
|
250
|
-
|
(3)
|
623
|
North America
|
174
|
111
|
277
|
86
|
1
|
(2)
|
647
|
Rest of the world
|
34
|
117
|
94
|
83
|
10
|
(114)
|
224
|
Total
|
650
|
845
|
1,131
|
973
|
93
|
(205)
|
3,487
|
Industrial Products
|
Potash
|
Phosphate Solutions
|
Growing Solutions
|
Other
Activities
|
Reconciliations
|
Consolidated
|
|
$ millions
|
For the year ended December 31, 2024
|
|||||||
Europe
|
391
|
478
|
542
|
731
|
128
|
(147)
|
2,123
|
Asia
|
438
|
352
|
613
|
249
|
31
|
(19)
|
1,664
|
South America
|
21
|
402
|
307
|
627
|
-
|
(4)
|
1,353
|
North America
|
329
|
202
|
567
|
170
|
3
|
(4)
|
1,267
|
Rest of the world
|
60
|
222
|
186
|
173
|
19
|
(226)
|
434
|
Total
|
1,239
|
1,656
|
2,215
|
1,950
|
181
|
(400)
|
6,841
|
June 30, 2025
|
June 30, 2024
|
December 31, 2024
|
||||
Carrying
amount
|
Fair
value
|
Carrying
amount
|
Fair
value
|
Carrying
amount |
Fair
value
|
|
$ millions
|
$ millions
|
$ millions
|
Loans bearing fixed interest
|
382
|
367
|
326
|
299
|
287
|
271
|
Debentures bearing fixed interest
|
||||||
Marketable
|
1,136
|
1,100
|
1,093
|
965
|
909
|
845
|
Non-marketable
|
47
|
47
|
47
|
46
|
47
|
47
|
1,565
|
1,514
|
1,466
|
1,310
|
1,243
|
1,163
|
Level 2
|
June 30,
2025
|
June 30,
2024
|
December 31,
2024
|
$ millions
|
$ millions
|
$ millions
|
Derivatives used for economic hedge, net
|
64
|
3
|
1
|
Derivatives designated as cash flow hedge, net
|
44
|
(18)
|
-
|
108
|
(15)
|
1
|
1. |
At the general meeting of shareholders, held on March 6, 2025, the shareholders approved a new three-year equity grant for the years 2025-2027 to the CEO and
the Chairman of the Board. The grant consists of about 4.3 million non-marketable and non-transferable options for no consideration, under the Company’s 2024 Equity Compensation Plan.
The options will vest in three tranches, after 12, 24 and 36 months from the grant date (March 6, 2025, for the Chairman of the Board and March 13, 2025, for the CEO). The options will expire in March 2030. The aggregate fair value at
the grant dates is about $7 million.
|
2. |
On March 24, 2025, and April 1, 2025, the Company’s HR & Compensation Committee and the Board of Directors, respectively, approved a new triennial equity
grant for the years 2025-2027 to two senior managers. The grant consists of 1.2 million non-marketable and non-transferable options for no consideration, under the Company’s 2024 Equity Compensation Plan. The options will vest in three tranches, after 12, 24 and 36 months from the grant dates (April 1, 2025 and May 1, 2025). The aggregate fair value at the grant dates was about $1.7 million.
|
3. |
On July 2, 2025, and July 6, 2025, the Company’s HR & Compensation Committee and the Board of Directors, respectively, approved a new triennial equity
grant for the years 2025-2027 to certain officers and senior managers. The grant consists of 3.2 million non-marketable and non-transferable options for no consideration, under the Company’s 2024 Equity Compensation Plan. The options will vest in three tranches, after 12, 24 and 36 months from the grant date. The aggregate fair value at the grant date was about $6.3 million.
|
B. |
Cash long-term incentive plan
|
C. |
Dividend distributions
|
Decision date for dividend distribution by
the Board of Directors
|
Actual date of dividend
distribution
|
Distributed
amount ($ millions)
|
Dividend per
share ($)
|
February 25, 2025
|
March 25, 2025
|
52
|
0.04
|
May 18, 2025
|
June 18, 2025
|
55
|
0.04
|
August 5, 2025 *
|
September 17, 2025
|
55
|
0.04
|
1. |
Further to Note 18 to the Annual Financial Statements regarding the Company’s pre-emptive request — prior to filing a petition — to advance the Barir
Detailed National Outline Plan (NOP) without delay, on July 9, 2025, the Company submitted a petition to the Israel's Supreme Court. In accordance with the Court's decision, the State is required to submit its response by September
2025.
|
2. |
Further to Note 18 to the Annual Financial Statements regarding the approval of the mining plan for the northern Oron area, on June 30, 2025, a petition was
filed with the Be'er Sheva District Court objecting to the District Committee for Planning and Construction's approval, alleging that the approval process involved material deficiencies. In accordance with the Court's decision from
July 2, 2025, the Company is required to submit its response by September 2025.
|
3. |
Note 18 to the
Annual Financial Statements includes disclosure regarding the Dead Sea Works concession and the publication of a draft report by the Israeli Accountant General, for public comments, addressing the preparations for the
expiration of the Company’s existing concession and the grant of a new concession in 2030 (the “Draft Report”). The Draft Report includes recommendations concerning, among other things, the payment regime to the State, the
potential inclusion of a minimum price in the tender, the concession period, and environmental considerations including rehabilitation and infrastructure obligations, as well as the imposition of additional regulatory costs
and responsibilities on the future concession holder. As stated in Note 18, the Company submitted its comments as part of
the public process and also participated in hearings held as part of this process.
According to publications by the Accountant General, following the completion of the public process regarding
the Draft Report, the state intends to initiate legislative procedures and publish a draft bill of law, based on the Draft Report and the public process during the second half of 2025 (the "Draft Bill"). To the best of the
Company’s understanding, the Draft Bill may outline the terms and arrangements related to the future concession and may also propose amendments or arrangements affecting the rights of the current concession holder under the
existing Concession Law, all as part of the State's wish to establish a tender process that serves its objectives. The Draft Bill will be subject to a full legislative process, including, among other steps, publication for
public comments, hearings and the stages of discussions and legislation in the Israeli parliament ("Knesset").
Upon publication of the Draft Bill, and to the extent it is published, the Company intends to thoroughly review
its provisions, respond within the framework of the public process, and, if necessary, take appropriate action to safeguard its rights and its legal and commercial interests.
|
4. |
Further to Note 18 to the Annual Financial Statements regarding ICL Rotem's new mining concession and the petition filed with Israel’s Supreme Court against
the competitive process and the disclosure certificate issued to the Company in connection with this process, on May 7, 2025, the Supreme Court rejected the petition.
|
5. |
Further to Note 18 to the Annual Financial Statements regarding the Israel Water Authority's decision that the Company's status should be changed to a
"Consumer-Producer", as defined in the Water Law, it was decided to postpone the hearing on the Company's appeal to January 2026.
|
|
ICL Group Ltd.
|
||
|
|
||
|
By:
|
/s/ Aviram Lahav
|
|
|
|
Name:
|
Aviram Lahav
|
|
|
Title:
|
Chief Financial Officer
|
|
ICL Group Ltd.
|
||
|
|
||
|
By:
|
/s/ Aya Landman
|
|
|
|
Name:
|
Aya Landman
|
|
|
Title:
|
VP, Chief Compliance Officer & Corporate Secretary
|
Source: